Research Analysts Set Expectations for RIGL Q3 Earnings

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) – HC Wainwright lifted their Q3 2026 earnings per share estimates for Rigel Pharmaceuticals in a note issued to investors on Friday, August 14th. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will post earnings per share of $0.99 for the quarter, up from their prior estimate of $0.68. HC Wainwright has a “Buy” rating and a $85.00 price objective on the stock. The consensus estimate for Rigel Pharmaceuticals’ current full-year earnings is $2.88 per share. HC Wainwright also issued estimates for Rigel Pharmaceuticals’ Q4 2026 earnings at $0.94 EPS, FY2026 earnings at $3.26 EPS, FY2027 earnings at $5.26 EPS, FY2028 earnings at $5.88 EPS, FY2029 earnings at $6.76 EPS and FY2030 earnings at $7.95 EPS.

Rigel Pharmaceuticals (NASDAQ:RIGL) last issued its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported $0.88 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.79. The firm had revenue of $78.70 million during the quarter, compared to analysts’ expectations of $55.27 million. Rigel Pharmaceuticals had a net margin of 116.30% and a return on equity of 22.95%.

A number of other equities research analysts have also recently issued reports on RIGL. Piper Sandler reissued a “neutral” rating and issued a $49.00 target price (up from $40.00) on shares of Rigel Pharmaceuticals in a research report on Monday. Zacks Research downgraded Rigel Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Thursday, May 7th. Weiss Ratings raised Rigel Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, August 6th. Finally, Citigroup reiterated a “buy” rating on shares of Rigel Pharmaceuticals in a research report on Thursday, August 6th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $59.00.

Rigel Pharmaceuticals Stock Down 0.3%

Shares of RIGL stock opened at $42.45 on Tuesday. The firm has a market capitalization of $785.41 million, a price-to-earnings ratio of 2.60 and a beta of 1.16. The firm has a fifty day moving average of $38.29 and a 200-day moving average of $33.20. Rigel Pharmaceuticals has a 12-month low of $24.95 and a 12-month high of $52.24.

Hedge Funds Weigh In On Rigel Pharmaceuticals

A number of hedge funds have recently made changes to their positions in RIGL. Empowered Funds LLC acquired a new stake in Rigel Pharmaceuticals during the 2nd quarter valued at approximately $3,098,000. Bank of America Corp DE bought a new stake in shares of Rigel Pharmaceuticals in the 2nd quarter valued at $4,832,000. Man Group plc acquired a new stake in shares of Rigel Pharmaceuticals during the second quarter worth $814,000. Jupiter Topco LLC acquired a new stake in shares of Rigel Pharmaceuticals during the second quarter worth $3,450,000. Finally, Hsbc Holdings PLC bought a new position in Rigel Pharmaceuticals during the second quarter worth $745,000. 66.23% of the stock is currently owned by institutional investors.

Insider Transactions at Rigel Pharmaceuticals

In other Rigel Pharmaceuticals news, Director Kamil Ali-Jackson sold 2,500 shares of Rigel Pharmaceuticals stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $35.00, for a total transaction of $87,500.00. Following the transaction, the director directly owned 10,125 shares of the company’s stock, valued at approximately $354,375. The trade was a 19.80% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 10.47% of the stock is currently owned by corporate insiders.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2003, Rigel focuses on the discovery, development and commercialization of novel small molecule therapeutics targeting immune, hematologic and oncologic diseases. Leveraging a proprietary chemistry platform and expertise in signal transduction pathways, the company aims to address significant unmet medical needs in both rare and common disorders.

Rigel’s lead product, fostamatinib (commercially known as Tavalisse®), is an oral spleen tyrosine kinase (SYK) inhibitor approved in the United States for the treatment of adult patients with chronic immune thrombocytopenia (ITP).